A Phase 1 interventional study of Dulaglutide and Placebo in Diabetes Mellitus, Type 2 and Healthy Volunteers, sponsored by Eli Lilly and Company. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-03-07.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 1 of them phase 3. dulaglutide · Diabetes Mellitus, Type 2.
Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, this one is the 39th largest by enrollment, is one of 8 that started in 2012, is one of 15 in phase 1, and was the 27th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Argentina, Mexico
Ages 10–17
First Affiliated Hospital of Wannan Medical College
Ages 18+
Seoul National University Bundang Hospital
Ages 20–90
By country, each count listing its studies:
dulaglutide: first FDA approval 2014 (TRULICITY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 6 · Phase 3 23 · Phase 4 9
First in 2008; this study’s year is marked. 8 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 58 is below the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 159 across the 54 interventional studies. Of the 47 that completed or were terminated, 38 (81%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 54 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company: 10 open now, 21 under way, 11 of them phase 3. Of 211 finished, 155 (73%) have results posted.
Among the 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company, this one is the 171st largest by enrollment of the 232 interventional ones that give a count, is one of 14 that started in 2012, is one of 76 in phase 1, and was the 90th registered.
Eli Lilly and Company’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
1 of the studies testing dulaglutide in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07537088First Affiliated Hospital of Wannan Medical CollegeEfficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 238 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This is a study of dulaglutide in Chinese participants. The purpose of the study is to determine how the body processes dulaglutide and how dulaglutide affects the body. This study has 2 parts: Part A - single dose of dulaglutide administered to healthy participants in 2 of 3 study periods. There is a minimum 28-day washout between periods. Part A will last approximately 16 weeks. Part B - multiple doses of dulaglutide administered to participants with Type 2 diabetes mellitus (T2DM). Part B will last approximately 15 weeks.
Doses of 0.5 milligrams (mg), 0.75 mg, and 1.5 mg of dulaglutide will be evaluated in this study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All Participants:
Participants with T2DM:
Exclusion Criteria:
All Participants:
Participants with T2DM
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
0.5 milligrams (mg) dulaglutide administered once subcutaneously (SQ) to healthy participants in 1 of 3 treatment periods
Drug: Dulaglutide · Drug: Placebo
0.75 mg dulaglutide administered once SQ to healthy participants in 1 of 3 treatment periods
Drug: Dulaglutide · Drug: Placebo
1.5 mg dulaglutide administered once SQ to healthy participants in 1 of 3 treatment periods
Drug: Dulaglutide · Drug: Placebo
Placebo administered once SQ to healthy participants in 1 of 3 treatment periods
Drug: Placebo
0.5 mg dulaglutide administered to participants with Type 2 diabetes mellitus (T2DM) once weekly SQ for 4 weeks
Drug: Dulaglutide · Drug: Placebo
0.75 mg dulaglutide administered to participants with T2DM once weekly SQ for 4 weeks
Drug: Dulaglutide · Drug: Placebo
1.5 mg dulaglutide administered to participants with T2DM once weekly SQ for 4 weeks
Drug: Dulaglutide · Drug: Placebo
Placebo administered to participants with T2DM once weekly SQ for 4 weeks
Drug: Placebo
Also known as: LY2189265
Administered SQ in the placebo arms and to maintain the blind in the dulaglutide arms.
Pharmacokinetics: Maximum Concentration (Cmax) of Dulaglutide
Pharmacokinetic parameters were assessed on Day 1 in Part A and Days 1 and 22 in Part B.
Time frame: Pre-dose and 12, 24, 48, 72, 96, 168, and 336 hours post-dose
Pharmacokinetics: Time of Maximum Observed Concentration (Tmax) of Dulaglutide
Pharmacokinetic parameters were assessed on Day 1 in Part A and Days 1 and 22 in Part B.
Time frame: Pre-dose and 12, 24, 48, 72, 96, 168, and 336 hours post-dose
Pharmacokinetics: Area Under the Concentration-time Curve From Time Zero to 336 Hours Postdose (AUC[0-336]) of Dulaglutide
Pharmacokinetic parameters were assessed on Day 1 in Part A and Days 1 and 22 in Part B.
Time frame: Pre-dose and 12, 24, 48, 72, 96, 168, and 336 hours post-dose
Pharmacokinetics: Half-life of Dulaglutide
Pharmacokinetic parameters were assessed on Day 1 in Part A and Days 1 and 22 in Part B.
Time frame: Pre-dose and 12, 24, 48, 72, 96, 168, and 336 hours post-dose
Part B - Pharmacodynamics: Area Under the Plasma Glucose Time Curve From Time Zero to 4 Hours Postmeal (gAUC[0-4])
Pharmacodynamic parameters were assessed at baseline and on Days 3, 24, and 29 in Part B.
Time frame: Baseline and Days 3, 24, and 29
| Milestone | First 0.5 mg, Then Placebo, Then 1.5 mg (Part A-Healthy) | First 0.75 mg, Then 0.5 mg, Then Placebo (Part A-Healthy) | First 0.75 mg, Then 1.5 mg, Then Placebo (Part A-Healthy) | First 0.5 mg, Then 1.5 mg, Then Placebo (Part A-Healthy) | First 1.5 mg, Then Placebo, Then 0.75 mg (Part A-Healthy) | First Placebo, Then 0.5 mg, Then 1.5 mg (Part A-Healthy) | First 0.75 mg, Then Placebo, Then 1.5 mg (Part A-Healthy) | First Placebo, Then 0.75 mg, Then 0.5 mg (Part A-Healthy) | First Placebo, Then 0.75 mg, Then 1.5 mg (Part A-Healthy) | First 0.5 mg, Then 0.75 mg, Then Placebo (Part A-Helathy) | First 1.5 mg, Then 0.75 mg, Then Placebo (Part A-Healthy) | First 0.5 mg, Then Placebo, Then 0.75 mg (Part A-Healthy) | First 0.75 mg, Then Placebo, Then 0.5 mg (Part A-Healthy) | First Placebo, Then 1.5 mg, Then 0.75 mg (Part A-Healthy) | First 1.5 mg, Then 0.5 mg, Then Placebo (Part A-Healthy) | First Placebo, Then 1.5 mg, Then 0.5 mg (Part A-Healthy) | 0.5 mg Dulaglutide (Part B-T2DM) | 0.75 mg Dulaglutide (Part B-T2DM) | 1.5 mg Dulaglutide (Part B-T2DM) | Placebo (Part B-T2DM) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Completed | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | First 0.5 mg, Then Placebo, Then 1.5 mg (Part A-Healthy) | First 0.75 mg, Then 0.5 mg, Then Placebo (Part A-Healthy) | First 0.75 mg, Then 1.5 mg, Then Placebo (Part A-Healthy) | First 0.5 mg, Then 1.5 mg, Then Placebo (Part A-Healthy) | First 1.5 mg, Then Placebo, Then 0.75 mg (Part A-Healthy) | First Placebo, Then 0.5 mg, Then 1.5 mg (Part A-Healthy) | First 0.75 mg, Then Placebo, Then 1.5 mg (Part A-Healthy) | First Placebo, Then 0.75 mg, Then 0.5 mg (Part A-Healthy) | First Placebo, Then 0.75 mg, Then 1.5 mg (Part A-Healthy) | First 0.5 mg, Then 0.75 mg, Then Placebo (Part A-Helathy) | First 1.5 mg, Then 0.75 mg, Then Placebo (Part A-Healthy) | First 0.5 mg, Then Placebo, Then 0.75 mg (Part A-Healthy) | First 0.75 mg, Then Placebo, Then 0.5 mg (Part A-Healthy) | First Placebo, Then 1.5 mg, Then 0.75 mg (Part A-Healthy) | First 1.5 mg, Then 0.5 mg, Then Placebo (Part A-Healthy) | First Placebo, Then 1.5 mg, Then 0.5 mg (Part A-Healthy) | 0.5 mg Dulaglutide (Part B-T2DM) | 0.75 mg Dulaglutide (Part B-T2DM) | 1.5 mg Dulaglutide (Part B-T2DM) | Placebo (Part B-T2DM) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Completed | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | First 0.5 mg, Then Placebo, Then 1.5 mg (Part A-Healthy) | First 0.75 mg, Then 0.5 mg, Then Placebo (Part A-Healthy) | First 0.75 mg, Then 1.5 mg, Then Placebo (Part A-Healthy) | First 0.5 mg, Then 1.5 mg, Then Placebo (Part A-Healthy) | First 1.5 mg, Then Placebo, Then 0.75 mg (Part A-Healthy) | First Placebo, Then 0.5 mg, Then 1.5 mg (Part A-Healthy) | First 0.75 mg, Then Placebo, Then 1.5 mg (Part A-Healthy) | First Placebo, Then 0.75 mg, Then 0.5 mg (Part A-Healthy) | First Placebo, Then 0.75 mg, Then 1.5 mg (Part A-Healthy) | First 0.5 mg, Then 0.75 mg, Then Placebo (Part A-Helathy) | First 1.5 mg, Then 0.75 mg, Then Placebo (Part A-Healthy) | First 0.5 mg, Then Placebo, Then 0.75 mg (Part A-Healthy) | First 0.75 mg, Then Placebo, Then 0.5 mg (Part A-Healthy) | First Placebo, Then 1.5 mg, Then 0.75 mg (Part A-Healthy) | First 1.5 mg, Then 0.5 mg, Then Placebo (Part A-Healthy) | First Placebo, Then 1.5 mg, Then 0.5 mg (Part A-Healthy) | 0.5 mg Dulaglutide (Part B-T2DM) | 0.75 mg Dulaglutide (Part B-T2DM) | 1.5 mg Dulaglutide (Part B-T2DM) | Placebo (Part B-T2DM) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Completed | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | First 0.5 mg, Then Placebo, Then 1.5 mg (Part A-Healthy) | First 0.75 mg, Then 0.5 mg, Then Placebo (Part A-Healthy) | First 0.75 mg, Then 1.5 mg, Then Placebo (Part A-Healthy) | First 0.5 mg, Then 1.5 mg, Then Placebo (Part A-Healthy) | First 1.5 mg, Then Placebo, Then 0.75 mg (Part A-Healthy) | First Placebo, Then 0.5 mg, Then 1.5 mg (Part A-Healthy) | First 0.75 mg, Then Placebo, Then 1.5 mg (Part A-Healthy) | First Placebo, Then 0.75 mg, Then 0.5 mg (Part A-Healthy) | First Placebo, Then 0.75 mg, Then 1.5 mg (Part A-Healthy) | First 0.5 mg, Then 0.75 mg, Then Placebo (Part A-Helathy) | First 1.5 mg, Then 0.75 mg, Then Placebo (Part A-Healthy) | First 0.5 mg, Then Placebo, Then 0.75 mg (Part A-Healthy) | First 0.75 mg, Then Placebo, Then 0.5 mg (Part A-Healthy) | First Placebo, Then 1.5 mg, Then 0.75 mg (Part A-Healthy) | First 1.5 mg, Then 0.5 mg, Then Placebo (Part A-Healthy) | First Placebo, Then 1.5 mg, Then 0.5 mg (Part A-Healthy) | 0.5 mg Dulaglutide (Part B-T2DM) | 0.75 mg Dulaglutide (Part B-T2DM) | 1.5 mg Dulaglutide (Part B-T2DM) | Placebo (Part B-T2DM) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Completed | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | First 0.5 mg, Then Placebo, Then 1.5 mg (Part A-Healthy) | First 0.75 mg, Then 0.5 mg, Then Placebo (Part A-Healthy) | First 0.75 mg, Then 1.5 mg, Then Placebo (Part A-Healthy) | First 0.5 mg, Then 1.5 mg, Then Placebo (Part A-Healthy) | First 1.5 mg, Then Placebo, Then 0.75 mg (Part A-Healthy) | First Placebo, Then 0.5 mg, Then 1.5 mg (Part A-Healthy) | First 0.75 mg, Then Placebo, Then 1.5 mg (Part A-Healthy) | First Placebo, Then 0.75 mg, Then 0.5 mg (Part A-Healthy) | First Placebo, Then 0.75 mg, Then 1.5 mg (Part A-Healthy) | First 0.5 mg, Then 0.75 mg, Then Placebo (Part A-Helathy) | First 1.5 mg, Then 0.75 mg, Then Placebo (Part A-Healthy) | First 0.5 mg, Then Placebo, Then 0.75 mg (Part A-Healthy) | First 0.75 mg, Then Placebo, Then 0.5 mg (Part A-Healthy) | First Placebo, Then 1.5 mg, Then 0.75 mg (Part A-Healthy) | First 1.5 mg, Then 0.5 mg, Then Placebo (Part A-Healthy) | First Placebo, Then 1.5 mg, Then 0.5 mg (Part A-Healthy) | 0.5 mg Dulaglutide (Part B-T2DM) | 0.75 mg Dulaglutide (Part B-T2DM) | 1.5 mg Dulaglutide (Part B-T2DM) | Placebo (Part B-T2DM) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Completed | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | First 0.5 mg, Then Placebo, Then 1.5 mg (Part A-Healthy) | First 0.75 mg, Then 0.5 mg, Then Placebo (Part A-Healthy) | First 0.75 mg, Then 1.5 mg, Then Placebo (Part A-Healthy) | First 0.5 mg, Then 1.5 mg, Then Placebo (Part A-Healthy) | First 1.5 mg, Then Placebo, Then 0.75 mg (Part A-Healthy) | First Placebo, Then 0.5 mg, Then 1.5 mg (Part A-Healthy) | First 0.75 mg, Then Placebo, Then 1.5 mg (Part A-Healthy) | First Placebo, Then 0.75 mg, Then 0.5 mg (Part A-Healthy) | First Placebo, Then 0.75 mg, Then 1.5 mg (Part A-Healthy) | First 0.5 mg, Then 0.75 mg, Then Placebo (Part A-Helathy) | First 1.5 mg, Then 0.75 mg, Then Placebo (Part A-Healthy) | First 0.5 mg, Then Placebo, Then 0.75 mg (Part A-Healthy) | First 0.75 mg, Then Placebo, Then 0.5 mg (Part A-Healthy) | First Placebo, Then 1.5 mg, Then 0.75 mg (Part A-Healthy) | First 1.5 mg, Then 0.5 mg, Then Placebo (Part A-Healthy) | First Placebo, Then 1.5 mg, Then 0.5 mg (Part A-Healthy) | 0.5 mg Dulaglutide (Part B-T2DM) | 0.75 mg Dulaglutide (Part B-T2DM) | 1.5 mg Dulaglutide (Part B-T2DM) | Placebo (Part B-T2DM) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11 | 11 | 10 | 10 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 11 | 10 | 10 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
Pharmacokinetic parameters were assessed on Day 1 in Part A and Days 1 and 22 in Part B.
| nanograms per milliliter (ng/mL) | 0.5 mg Dulaglutide (Part A-Healthy) | 0.75 mg Dulaglutide (Part A-Healthy) | 1.5 mg Dulaglutide (Part A-Healthy) | 0.5 mg Dulaglutide (Part B-T2DM) | 0.75 mg Dulaglutide (Part B-T2DM) | 1.5 mg Dulaglutide (Part B-T2DM) |
|---|---|---|---|---|---|---|
| Day 1 (Parts A and B) | 29.4 ± 39 | 44.2 ± 14 | 81.5 ± 21 | 20.7 ± 18 | 31.3 ± 23 | 52.6 ± 28 |
| Day 22 (Part B only) | NA ± NA | NA ± NA | NA ± NA | 26.3 ± 27 | 41.4 ± 18 | 70.2 ± 19 |
Pharmacokinetic parameters were assessed on Day 1 in Part A and Days 1 and 22 in Part B.
| hours | 0.5 mg Dulaglutide (Part A-Healthy) | 0.75 mg Dulaglutide (Part A-Healthy) | 1.5 mg Dulaglutide (Part A-Healthy) | 0.5 mg Dulaglutide (Part B-T2DM) | 0.75 mg Dulaglutide (Part B-T2DM) | 1.5 mg Dulaglutide (Part B-T2DM) |
|---|---|---|---|---|---|---|
| Day 1 (Parts A and B) | 48.02 (12.02 to 48.02) | 48.00 (24.00 to 48.00) | 48.00 (24.00 to 48.00) | 48.00 (47.92 to 72.00) | 48.00 (24.00 to 72.00) | 71.98 (24.00 to 96.00) |
| Day 22 (Part B only) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | 48.00 (12.00 to 48.02) | 47.98 (24.00 to 48.00) | 48.00 (23.97 to 96.00) |
Pharmacokinetic parameters were assessed on Day 1 in Part A and Days 1 and 22 in Part B.
| nanograms*hours per milliliter (ng*h/mL) | 0.5 mg Dulaglutide (Part A-Healthy) | 0.75 mg Dulaglutide (Part A-Healthy) | 1.5 mg Dulaglutide (Part A-Healthy) | 0.5 mg Dulaglutide (Part B-T2DM) | 0.75 mg Dulaglutide (Part B-T2DM) | 1.5 mg Dulaglutide (Part B-T2DM) |
|---|---|---|---|---|---|---|
| Day 1 (Parts A and B; n = 6, 10, 11, 3, 8, 4) | 4500 ± 42 | 6410 ± 14 | 11700 ± 12 | 3900 ± 7 | 5490 ± 19 | 10300 ± 16 |
| Day 22 (Part B only; n = 6, 10, 10 | NA ± NA | NA ± NA | NA ± NA | 4720 ± 7 | 7030 ± 17 | 12500 ± 15 |
Pharmacokinetic parameters were assessed on Day 1 in Part A and Days 1 and 22 in Part B.
| hours | 0.5 mg Dulaglutide (Part A-Healthy) | 0.75 mg Dulaglutide (Part A-Healthy) | 1.5 mg Dulaglutide (Part A-Healthy) | 0.5 mg Dulaglutide (Part B-T2DM) | 0.75 mg Dulaglutide (Part B-T2DM) | 1.5 mg Dulaglutide (Part B-T2DM) |
|---|---|---|---|---|---|---|
| Day 1 (Parts A and B; n=6, 10, 11, 3, 8, 4) | 85.1 (50.8 to 244) | 84.5 (60.2 to 228) | 82.9 (63.8 to 104) | 122 (106 to 133) | 113 (63.9 to 222) | 88.5 (69.6 to 111) |
| Day 22 (Part B only; n=NA, NA, NA, 6, 10, 9) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | 97.6 (71.9 to 122) | 106 (70.4 to 139) | 105 (80.0 to 134) |
Pharmacodynamic parameters were assessed at baseline and on Days 3, 24, and 29 in Part B.
| millimoles*hours per liter (mmol*h/L) | 0.5 mg Dulaglutide (Part B-T2DM) | 0.75 mg Dulaglutide (Part B-T2DM) | 1.5 mg Dulaglutide (Part B-T2DM) | Placebo (Part B-T2DM |
|---|---|---|---|---|
| Baseline | 44.3 ± 10.6 | 58.1 ± 11.7 | 53.4 ± 8.12 | 48.2 ± 7.00 |
| Day 3 | 34.2 ± 6.19 | 41.2 ± 11.9 | 32.2 ± 4.87 | 46.1 ± 8.94 |
| Day 24 | 34.7 ± 7.11 | 36.8 ± 7.08 | 30.5 ± 4.55 | 48.6 ± 9.10 |
| Day 29 | 37.6 ± 9.11 | 38.1 ± 7.40 | 31.8 ± 4.57 | 46.9 ± 6.68 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo (Part A-Healthy) | — | 0/16 (0%) | 1/16 (6.3%) |
| 0.5 mg Dulaglutide (Part A-Healthy) | — | 0/10 (0%) | 0/10 (0%) |
| 0.75 mg Dulaglutide (Part A-Healthy) | — | 0/11 (0%) | 2/11 (18.2%) |
| 1.5 mg Dulaglutide (Part A-Healthy) | — | 0/11 (0%) | 4/11 (36.4%) |
| Placebo (Part B-T2DM) | — | 0/10 (0%) | 1/10 (10%) |
| 0.5 mg Dulaglutide (Part B-T2DM) | — | 1/11 (9.1%) | 5/11 (45.5%) |
| 0.75 mg Dulaglutide (Part B-T2DM) | — | 0/11 (0%) | 5/11 (45.5%) |
| 1.5 mg Dulaglutide (Part B-T2DM) | — | 0/10 (0%) | 2/10 (20%) |
| Event | Placebo (Part A-Healthy) | 0.5 mg Dulaglutide (Part A-Healthy) | 0.75 mg Dulaglutide (Part A-Healthy) | 1.5 mg Dulaglutide (Part A-Healthy) | Placebo (Part B-T2DM) | 0.5 mg Dulaglutide (Part B-T2DM) | 0.75 mg Dulaglutide (Part B-T2DM) | 1.5 mg Dulaglutide (Part B-T2DM) |
|---|---|---|---|---|---|---|---|---|
| Myocardial infarctionCardiac disorders | 0/16 | 0/10 | 0/11 | 0/11 | 0/10 | 1/11 | 0/11 | 0/10 |
| Event | Placebo (Part A-Healthy) | 0.5 mg Dulaglutide (Part A-Healthy) | 0.75 mg Dulaglutide (Part A-Healthy) | 1.5 mg Dulaglutide (Part A-Healthy) | Placebo (Part B-T2DM) | 0.5 mg Dulaglutide (Part B-T2DM) | 0.75 mg Dulaglutide (Part B-T2DM) | 1.5 mg Dulaglutide (Part B-T2DM) |
|---|---|---|---|---|---|---|---|---|
| Decreased appetiteMetabolism and nutrition disorders | 0/16 | 0/10 | 0/11 | 2/11 | 0/10 | 2/11 | 2/11 | 1/10 |
| Abdominal discomfortGastrointestinal disorders | 1/16 | 0/10 | 1/11 | 1/11 | 0/10 | 1/11 | 1/11 | 1/10 |
| NauseaGastrointestinal disorders | 0/16 | 0/10 | 1/11 | 1/11 | 0/10 | 0/11 | 0/11 | 1/10 |
| VomitingGastrointestinal disorders | 0/16 | 0/10 | 1/11 | 0/11 | 0/10 | 0/11 | 0/11 | 1/10 |
| Blood glucose increasedInvestigations | 0/16 | 0/10 | 0/11 | 0/11 | 1/10 | 0/11 | 0/11 | 0/10 |
| LeukopeniaBlood and lymphatic system disorders | 0/16 | 0/10 | 0/11 | 0/11 | 0/10 | 1/11 | 0/11 | 0/10 |
| Atrial tachycardiaCardiac disorders | 0/16 | 0/10 | 0/11 | 0/11 | 0/10 | 1/11 | 0/11 | 0/10 |
| TachycardiaCardiac disorders | 0/16 | 0/10 | 0/11 | 0/11 | 0/10 | 1/11 | 0/11 | 0/10 |
| Abdominal distensionGastrointestinal disorders | 0/16 | 0/10 | 0/11 | 0/11 | 0/10 | 0/11 | 1/11 | 0/10 |
| Abdominal painGastrointestinal disorders | 0/16 | 0/10 | 0/11 | 0/11 | 0/10 | 1/11 | 0/11 | 0/10 |
All enrolled participants.
| Age, Continuous(years) | Part A-Healthy | 0.5 mg Dulaglutide (Part B-T2DM) | 0.75 mg Dulaglutide (Part B-T2DM) | 1.5 mg Dulaglutide (Part B-T2DM) | Placebo (Part B-T2DM) | Total |
|---|---|---|---|---|---|---|
| Mean | 29.2 ± 5.6 | 58.2 ± 4.2 | 56.9 ± 13.1 | 55.8 ± 8.5 | 51.8 ± 8.3 | 48.4 ± 14.5 |
| Sex: Female, Male(Participants) | Part A-Healthy | 0.5 mg Dulaglutide (Part B-T2DM) | 0.75 mg Dulaglutide (Part B-T2DM) | 1.5 mg Dulaglutide (Part B-T2DM) | Placebo (Part B-T2DM) | Total |
|---|---|---|---|---|---|---|
| Female | 0 | 3 | 3 | 3 | 3 | 12 |
| Male | 16 | 8 | 8 | 7 | 7 | 46 |
| Ethnicity (NIH/OMB)(Participants) | Part A-Healthy | 0.5 mg Dulaglutide (Part B-T2DM) | 0.75 mg Dulaglutide (Part B-T2DM) | 1.5 mg Dulaglutide (Part B-T2DM) | Placebo (Part B-T2DM) | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 16 | 11 | 11 | 10 | 10 | 58 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Part A-Healthy | 0.5 mg Dulaglutide (Part B-T2DM) | 0.75 mg Dulaglutide (Part B-T2DM) | 1.5 mg Dulaglutide (Part B-T2DM) | Placebo (Part B-T2DM) | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 16 | 11 | 11 | 10 | 10 | 58 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Part A-Healthy | 0.5 mg Dulaglutide (Part B-T2DM) | 0.75 mg Dulaglutide (Part B-T2DM) | 1.5 mg Dulaglutide (Part B-T2DM) | Placebo (Part B-T2DM) | Total |
|---|---|---|---|---|---|---|
| China | 16 | 11 | 11 | 10 | 10 | 58 |
The record gives a start of Aug 2012, a primary completion of Jun 2014 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2016, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dulaglutide